Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 18Carcinoma, Hepatocellular 18Stomach Neoplasms 12Esophageal Squamous Cell Carcinoma 12Squamous Cell Carcinoma of Head and Neck 9Neoplasm Metastasis 9Advanced Solid Tumor 9Lung Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 5Esophageal Neoplasms 5Small Cell Lung Carcinoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Solid Tumor 3Lymphoma, Follicular 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2

Interventions

Cyclophosphamide 34Doxorubicin 24fludarabine phosphate 20Vinblastine 20Nivolumab 20Dacarbazine 20Brentuximab Vedotin 20pembrolizumab 19fludarabine 18Mycophenolic Acid 17Whole-Body Irradiation 15Etoposide 15Filgrastim 13Melphalan 12Granulocyte Colony-Stimulating Factor 10Gemcitabine 10Bleomycin 10Tacrolimus 9Radiotherapy 9Prednisone 9Peripheral Blood Stem Cell Transplantation 9Busulfan 9Specimen Handling 8Vincristine 7Sirolimus 7Magnetic Resonance Spectroscopy 7Cyclosporine 7pegfilgrastim 6Stem Cell Transplantation 6Bendamustine Hydrochloride 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hodgkin Disease × tislelizumab × 1 year × Clear all
NCT05502250 2026-03-06

HOVON164HL

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Hodgkin Disease

NCT05977673 2025-12-08

FIL_Tisle-HL

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting
28 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡